Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2

References

• Estey E H. Prognostic factors in acute myelogenous leukemia. Leukemia 2001; 15: 670–672
   PubMed Web of Science ®Google Scholar
• Kelly L M, Gilliland D G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179–198
   PubMed Web of Science ®Google Scholar
• Deininger M W, Goldman J M, Melo J V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 2005; 84: 487–497
   PubMed Web of Science ®Google Scholar
• Bennett J M. The myelodysplastic/myeloproliferative disorders: the interface. Hematol Oncol Clin North Am 2003; 17: 1095–1100
   PubMed Web of Science ®Google Scholar
• Strout M P, Marcucci G, Caligiuri M A, Bloomfield C D. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999; 78: 251–264
   PubMed Web of Science ®Google Scholar
• Sattler M, Scheijen B, Weisberg E, Griffin J D. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003; 532: 121–140
   PubMed Web of Science ®Google Scholar
• Zhou J, Mauerer K, Farina L, Gribben J G. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci 2005; 10: 1581–1596
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplatic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Bellamy W, Richter L, Frutiger Y, Grogan T M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1998; 59: 728–733
   Web of Science ®Google Scholar
• Bellamy W T, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H M, Estey E H, Giles F J, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923–1930
   PubMed Web of Science ®Google Scholar
• Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Haematother Stem Cell Res 2002; 11: 119–125
   PubMedGoogle Scholar
• Ghannadan M, Wimazal F, Simonitsch I, Sperr W R, Mayerhofer M, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003; 119: 663–671
   PubMed Web of Science ®Google Scholar
• Krauth M T, Simonitsch I, Aichberger K J, Mayerhofer M, Sperr W R, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J Clin Pathol 2004; 121: 473–481
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovascular Res 2001; 49: 568–581
   PubMed Web of Science ®Google Scholar
• Fons P, Herault J P, Delesque N, Tuyaret J, Bono F, Herbert J M. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 2004; 200: 351–359
   PubMed Web of Science ®Google Scholar
• Santos C S, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103: 3883–3889
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857–10862
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma 2004; 45: 1887–1897
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 2003; 27: 661–669
   PubMed Web of Science ®Google Scholar
• Vardiman J W. Chronic myelogenous leukaemia. World Health Organization (WHO) Classification of Tumours. Pathology and Genetics, E S Jaffe, N L Harris, H Stein, J W Vardiman. Tumours of Haematopoietic and Lymphoid Tissues. 2001; 1: 20–26
   Google Scholar
• Vardiman J W, Imbert M, Pierre R, Brunning R D, Bain B, Flandrin G, . Chronic myelomonocytic leukemia. World Health Organization (WHO) Classification of Tumours. Pathology and Genetics, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. Tumours of Haematopoietic and Lymphoid Tissues. 2001; 1: 49–52
   Google Scholar
• Brunning R D, Vardiman J W, Matutes E, Bennett J M, Harris N L, Head D, . Acute myeloid leukemia. World Health Organization (WHO) Classification of Tumours. Pathology and Genetics, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. Tumours of Haematopoietic and Lymphoid Tissues. 2001; 1: 77–105
   Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Proposals for the classification of the acute leukaemias. French – American – British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Aichberger K J, Florian S, Krauth M T, Hauswirth A W, Derdak S, et al. Identification of mTOR as a novel bi-functional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 2005; 19: 960–962
   PubMed Web of Science ®Google Scholar
• Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998; 273: 18165–18172
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D, Weich H A, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336–3343
   PubMed Web of Science ®Google Scholar
• Goan S R, Junghahn I, Wissler M, Becker M, Aumann J, Just U, et al. Donor stromal cells from human blood engraft in NOD/SCID mice. Blood 2000; 96: 3971–3978
   PubMed Web of Science ®Google Scholar
• Beierle E A, Dai W, Langham M R, Jr, Copeland E M, III, Chen M K. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004; 119: 56–65
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Valent P, Sperr W R, Griffin J D, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767–3775
   PubMed Web of Science ®Google Scholar
• Agis H, Krauth M T, Mosberger I, Mullauer L, Simonitsch-Klupp I, Schwartz L B, et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006; 59: 396–402
   PubMed Web of Science ®Google Scholar
• Kreuter M, Woelke K, Bieker R, Schliemann C, Steins M, Buechner T, et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 2006; 20: 1950–1964
   PubMed Web of Science ®Google Scholar
• Schuch G, Machluf M, Bartsch G, Jr, Nomi M, Richard H, Atala A, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002; 100: 4622–4628
   PubMed Web of Science ®Google Scholar
• Bachelder R E, Crago A, Chung J, Wendt M A, Shaw L M, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736–5740
   PubMed Web of Science ®Google Scholar
• Nagata H, Worobec A S, Oh C K, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560–10564
   PubMed Web of Science ®Google Scholar
• Fritsche-Polanz R, Jordan J H, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357–364
   PubMed Web of Science ®Google Scholar
• Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp Hematol 2003; 31: 686–692
   PubMed Web of Science ®Google Scholar
• Wimazal F, Jordan J H, Sperr W R, Chott A, Dabbass S, Lechner K, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol 2002; 160: 1639–1645
   PubMed Web of Science ®Google Scholar
• Wimazal F, Krauth M T, Vales A, Bohm A, Agis H, Sonneck K, et al. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 2006; 47: 451–460
   PubMed Web of Science ®Google Scholar